<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Intensity Therapeutics Announces Reverse Stock Split</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Intensity Therapeutics Announces Reverse Stock Split</h1>

    <table>
      <tr><th>Ticker</th><td>INTS</td></tr>
      <tr><th>Float</th><td>55.5 M</td></tr>
      <tr><th>IO</th><td>7.69%</td></tr>
      <tr><th>MC</th><td>21.8 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Intensity Therapeutics (Nasdaq: INTS) announced a board- and shareholder-approved 1-for-25 reverse stock split effective 4:01 p.m. ET on Feb. 18, 2026. The company's common stock will trade on a post-split adjusted basis under the existing ticker INTS and new CUSIP 45828J202 on Nasdaq beginning Feb. 19, 2026. The reverse split will reduce outstanding shares from approximately 63,346,579 (as of Feb. 12, 2026) to approximately 2,533,863. No fractional shares will be issued; holders entitled to fractional shares will receive cash in lieu based on the closing price on Feb. 18, 2026 (post-split adjusted). Proportional adjustments will be made to exercise/conversion prices and share counts for stock options, warrants, convertible securities, and equity incentive plans. The company says the reverse split is intended to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Reverse split intended to increase per-share trading price to seek regaining Nasdaq minimum bid price compliance</li><li>Outstanding shares will be reduced from ~63.35M to ~2.53M (1-for-25), increasing per-share base mathematically</li><li>Post-split trading will occur under existing ticker (INTS) on Nasdaq starting Feb. 19, 2026; new CUSIP 45828J202 assigned</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Company required a reverse split to attempt to cure non-compliance with Nasdaq minimum bid price requirements</li><li>Holders of fractional shares will receive cash in lieu rather than fractional stock</li><li>Total authorized shares are not reduced, preserving capacity for future dilution</li></ul>
    </div>

    <div class="section">
      <a href="https://www.prnewswire.com/news-releases/intensity-therapeutics-announces-reverse-stock-split-302687690.html" target="_blank">Original Article</a>
    </div>

    <div class="small">INTS â€¢ TradersLink AI News</div>
  </div>
</body>
</html>